Novartis plans to seek quick regulatory approvals from health authorities for the drug, known as GanLum, which would be the ...

Dr. Ghyslain Mombo-Ngoma led a study in Gabon in which researchers gave a single-dose treatment combining an artemisinin with ...

Download the latest edition Overall, Baum and colleagues have identified how this new class of antimalarials block the parasite reaching sexual maturity, and therefore, their spread from human to ...

A novel class of antimalarial compounds that can effectively kill malaria parasites has been developed. In preclinical testing, the compounds were effective against different species of malaria ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

The best drug to fight malaria is facing increased resistance from the parasites it fights. Now there's an alternative in the pipeline and it looks promising.

Novartis (NOVN.S) has announced the successful completion of a pivotal Phase III trial for its new antimalarial drug, ganaplacide/lumetantrine, branded as GanLum, demonstrating effectiveness on par ...

PHILADELPHIA, March 5, 2025 /PRNewswire/ -- Antimalarial drug resistance is a pressing issue in combating the spread of malaria worldwide. In a new study, researchers from Children's Hospital of ...

This cartoon shows the newly identified mefloquine binding site causing the changes in the ribosome's dynamics which promote read-through of the premature stop codons. The main interactions are shown ...

The antimalarial drug mefloquine could help treat genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, as well as some cancers. In these diseases, a mutation in the genetic code ...

Researchers on Wednesday reported two promising new approaches to counteract malaria's growing resistance to medication — one ...